Cycad Group

Prelude is a technology company founded in 2018 and headquartered in Manchester, New Hampshire, that focuses on enhancing cybersecurity defenses for organizations. The company develops products that enable continuous probing of security systems, allowing users to ask critical questions related to their security posture. By translating complex security concepts into actionable inquiries, Prelude provides comprehensive internal intelligence that helps customers identify vulnerabilities and prioritize responses to potential threats. In addition to its technological offerings, Prelude Institute, a subsidiary, is dedicated to addressing the skills gap in the labor market by training individuals for middle-skills careers, particularly in cybersecurity. The institute aims to retrain workers from other industries into security analysts within six months, significantly improving their earning potential and contributing to the workforce's adaptability in a rapidly evolving job landscape.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

Lixivia, Inc. is a venture-backed start-up based in Santa Barbara, California, founded in 2012. The company specializes in developing innovative processes for the purification and separation of minerals, focusing on cost-effectiveness and scalability. Lixivia addresses critical challenges in re-purposing steel slag by stabilizing it for civil engineering applications and producing high-purity calcium minerals. The company utilizes advanced chemical engineering techniques to refine a variety of mineral mixtures, including low-grade lime, dolime, steel and iron slag, rare earth metals, and lithium. By optimizing these processes, Lixivia enables clients to maximize the value derived from their mineral resources while also reducing emissions associated with mineral extraction.

Formetrix Metals designs patented steel alloys for 3D printed components.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Agile RF Systems focuses on the design and development of advanced wireless systems for various applications, including communications, radar, and remote sensing. The company creates small, tactical radars specifically for weather monitoring and counter-unmanned aerial systems (UAS) purposes. Additionally, Agile RF Systems offers satellite communication solutions and develops active electronically steered antennas, as well as millimeter-wave antennas, which facilitate enhanced communication capabilities. By integrating these technologies with multi-channel software-defined radios, the company aims to provide innovative solutions that meet the evolving needs of its clients in the wireless communications sector.

ClarVista Medical, Inc. is a California-based company focused on developing innovative products to address challenging ophthalmic conditions. Founded in 2012, it specializes in the HARMONI modular intraocular lens system, which enhances vision optimization during cataract surgery. The company emerged from Prospex Medical, a medical device incubator, and has since developed a robust portfolio of intellectual property. ClarVista Medical has successfully completed the first generation of the HARMONI system and conducted initial human clinical studies. It is currently working on the second generation of the HARMONI system, aiming to conduct larger clinical trials and secure essential regulatory approvals. The company's technology allows for the initial positioning of the lens and facilitates easy exchange of the lens optic, thereby providing healthcare practitioners with a customizable solution for cataract surgery tailored to individual patient needs.

SOFIE focuses on advancing the field of theranostics by simplifying the adoption and application of molecular imaging and radiopharmaceuticals. The company offers a comprehensive range of imaging and radiochemistry systems, along with a robust network of radiopharmacies and contract manufacturing services to provide novel diagnostic and therapeutic agents. By developing molecular imaging probes and devices, SOFIE enables physicians to identify tumors that are responsive to targeted therapies, thereby facilitating personalized healthcare and informed treatment decisions. The company's commitment to reducing the cost and complexity of these technologies aims to enhance patient health outcomes.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

SOFIE focuses on advancing the field of theranostics by simplifying the adoption and application of molecular imaging and radiopharmaceuticals. The company offers a comprehensive range of imaging and radiochemistry systems, along with a robust network of radiopharmacies and contract manufacturing services to provide novel diagnostic and therapeutic agents. By developing molecular imaging probes and devices, SOFIE enables physicians to identify tumors that are responsive to targeted therapies, thereby facilitating personalized healthcare and informed treatment decisions. The company's commitment to reducing the cost and complexity of these technologies aims to enhance patient health outcomes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

OvaScience, Inc. was a fertility company focused on developing innovative treatments for women facing infertility challenges. The company was founded in 2011 and was headquartered in Waltham, Massachusetts. OvaScience specialized in proprietary technology derived from the discovery of egg precursor (EggPC) cells, which allowed for the enhancement of egg quality and improved outcomes in in vitro fertilization (IVF). Their treatment options included OvaPrime, which aimed to restore a woman's egg production using her own EggPC cells, OvaTure, designed to mature these cells into fertilizable eggs outside the body, and AUGMENT, which utilized mitochondria from EggPC cells to enhance fertilization and pregnancy rates. The company also explored OvaXon for preventing inherited diseases. OvaScience was co-founded by a team of experts from Harvard Medical School and was backed by prominent life science investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

Iosil Energy Corporation produces "high purity polysilicon," the essential raw material for solar cells. The Corporation was founded in 2007, with its R&D facilities located in the National Institute for Nanotechnology In Edmonton, Alberta. The company has demonstrated its ability to produce high-purity solar grade polysilicon from the waste material (or “kerf”) created by wafer sawing operations, saving costs.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

SOFIE focuses on advancing the field of theranostics by simplifying the adoption and application of molecular imaging and radiopharmaceuticals. The company offers a comprehensive range of imaging and radiochemistry systems, along with a robust network of radiopharmacies and contract manufacturing services to provide novel diagnostic and therapeutic agents. By developing molecular imaging probes and devices, SOFIE enables physicians to identify tumors that are responsive to targeted therapies, thereby facilitating personalized healthcare and informed treatment decisions. The company's commitment to reducing the cost and complexity of these technologies aims to enhance patient health outcomes.

Solaria Corporation specializes in the design, development, and manufacturing of silicon photovoltaic (PV) products, primarily serving solar system integrators, project developers, and large commercial and utility clients across the United States, Europe, and other international markets. The company offers crystalline solar modules tailored for various mounting systems and installation processes, along with tracking systems that enhance energy capture. In addition to its product offerings, Solaria provides services such as preliminary system design, energy yield optimization, and guidance on balance of system costs. The company also supports its clients with technical specifications, installation assistance, troubleshooting, and after-sales services. Founded in 1993 and originally known as Lightchip, Inc., Solaria Corporation is headquartered in Oakland, California, and has additional operations in Germany, India, and China.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

PsiloQuest develops and commercializes CMP polishing pads for the semiconductor industry.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.